There exists a requirement for drugs which would be useful in therapy of an acute radiation damage of a mammalian organism. The aim of the study was to evaluate survival parameters in mice exposed to a lethal γ-ray dose of 8.5 Gy and treated with single doses of an adenosine A(3) receptor agonist, IB-MECA, or a cyclooxygenase-2 (COX-2) inhibitor, meloxicam, administered alone or in a combination early after irradiation, i.e., 0.5 and 1 h post-irradiation, respectively. The assessed parameters were the mean survival time (MST) and the cumulative percentage 30-day survival (CPS). Administrations of single intraperitoneal doses of either IB-MECA 0.5 h post-irradiation or meloxicam 1 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice. Combined administration of IB-MECA and meloxicam was found to be the only treatment statistically enhancing the parameter of CPS and to lead to the most expressive increase in MST of the experimental mice. The findings add new knowledge on the action of an adenosine A3 receptor agonist and a COX-2 inhibitor in an irradiated mammalian organism and suggest the potential of both the investigated drugs in the treatment of the acute radiation damage.

Department of Molecular Cytology and Cytometry Institute of Biophysics v v i Academy of Sciences of the Czech Republic Královopolská 135 61265 Brno Czech Republic

Zobrazit více v PubMed

J Clin Invest. 1996 May 1;97(9):2145-51 PubMed

Exp Hematol. 2002 Dec;30(12):1390-8 PubMed

J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7 PubMed

Haematologica. 2008 Mar;93(3):465-6 PubMed

Exp Hematol. 2008 Jul;36(7):769-70; author reply 771-2 PubMed

Exp Hematol. 2005 Oct;33(10):1071-80 PubMed

Blood Cells Mol Dis. 2013 Mar;50(3):147-53 PubMed

Molecules. 2012 May 10;17(5):5615-25 PubMed

Mol Med Rep. 2013 Jun;7(6):1723-5 PubMed

Physiol Res. 2008;57(2):307-310 PubMed

J Rheumatol. 2008 Jan;35(1):41-8 PubMed

Radiat Res. 2009 Dec;172(6):686-97 PubMed

Biomed Pharmacother. 2007 Jul;61(6):356-9 PubMed

Biomed Pharmacother. 2011 Sep;65(6):427-31 PubMed

Radiat Res. 2005 Jan;163(1):115-23 PubMed

Physiol Res. 2012;61(6):649-54 PubMed

Eur J Pharmacol. 2006 May 24;538(1-3):163-7 PubMed

Radiat Environ Biophys. 1979 Feb 23;16(1):29-41 PubMed

Int J Radiat Biol. 1990 Apr;57(4):709-22 PubMed

Radiat Res. 2008 Nov;170(5):566-71 PubMed

Exp Biol Med (Maywood). 2008 Jul;233(7):897-900 PubMed

Radiat Res. 2011 Aug;176(2):269-72 PubMed

Exp Hematol. 1977 Sep;5(5):357-73 PubMed

Arthritis Rheum. 2010 Jun;62(6):1592-601 PubMed

Molecules. 2011 Jan 17;16(1):675-85 PubMed

Physiol Res. 2004;53(5):549-56 PubMed

Blood. 2003 Apr 1;101(7):2609-16 PubMed

Int J Radiat Biol. 2004 Jan;80(1):3-10 PubMed

Exp Hematol. 1980 Oct;8(9):1157-64 PubMed

Int J Radiat Biol. 2010 Aug;86(8):649-56 PubMed

Radiat Res. 2006 Sep;166(3):556-60 PubMed

Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome

Impaired post-irradiation survival of cyclooxygenase-2-deficient mice

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review